- Home
- CAPR vs KIO Comparison
CAPR vs KIO Comparison
Compare CAPR & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- KIO
- Stock Information
- Founded
- CAPR 2005
- KIO 2011
- Country
- CAPR United States
- KIO United States
- Employees
- CAPR N/A
- KIO 2400
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- KIO Investment Managers
- Sector
- CAPR Health Care
- KIO Finance
- Exchange
- CAPR Nasdaq
- KIO Nasdaq
- Market Cap
- CAPR 578.4M
- KIO 525.6M
- IPO Year
- CAPR N/A
- KIO N/A
- Fundamental
- Price
- CAPR $15.00
- KIO $12.65
- Analyst Decision
- CAPR Strong Buy
- KIO
- Analyst Count
- CAPR 7
- KIO 0
- Target Price
- CAPR $39.29
- KIO N/A
- AVG Volume (30 Days)
- CAPR 902.1K
- KIO 136.5K
- Earning Date
- CAPR 03-03-2025
- KIO 01-01-0001
- Dividend Yield
- CAPR N/A
- KIO 10.82%
- EPS Growth
- CAPR N/A
- KIO N/A
- EPS
- CAPR N/A
- KIO N/A
- Revenue
- CAPR $23,228,045.00
- KIO N/A
- Revenue This Year
- CAPR N/A
- KIO N/A
- Revenue Next Year
- CAPR $74.85
- KIO N/A
- P/E Ratio
- CAPR N/A
- KIO N/A
- Revenue Growth
- CAPR 65.33
- KIO N/A
- 52 Week Low
- CAPR $3.52
- KIO $10.52
- 52 Week High
- CAPR $23.40
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- CAPR 52.56
- KIO 35.85
- Support Level
- CAPR $14.28
- KIO $12.75
- Resistance Level
- CAPR $16.47
- KIO $12.95
- Average True Range (ATR)
- CAPR 1.00
- KIO 0.11
- MACD
- CAPR 0.07
- KIO 0.01
- Stochastic Oscillator
- CAPR 55.05
- KIO 23.86
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.